Edition:
United Kingdom

Biocept Inc (BIOC.OQ)

BIOC.OQ on NASDAQ Stock Exchange Capital Market

1.04USD
22 Mar 2019
Change (% chg)

$-0.01 (-0.95%)
Prev Close
$1.05
Open
$1.05
Day's High
$1.05
Day's Low
$0.99
Volume
255,669
Avg. Vol
379,603
52-wk High
$12.12
52-wk Low
$0.66

Chart for

About

Biocept, Inc. is an early commercial-stage molecular oncology diagnostics company. The Company develops and commercializes circulating tumor cell (CTC) and circulating tumor deoxyribonucleic acid (ctDNA), assays utilizing a standard blood sample, or liquid biopsy. The Company's Target-Selector offering is based on an internally... (more)

Overall

Beta: 3.04
Market Cap(Mil.): $39.03
Shares Outstanding(Mil.): 30.25
Dividend: --
Yield (%): --

Financials

  BIOC.OQ Industry Sector
P/E (TTM): -- 32.18 32.54
EPS (TTM): -1.26 -- --
ROI: -328.01 13.74 13.82
ROE: -550.52 16.44 15.24

BRIEF-Biocept And Prognos Enter Into Partnership

* BIOCEPT AND PROGNOS ENTER INTO PARTNERSHIP TO APPLY ARTIFICIAL INTELLIGENCE IN ORDER TO HELP PHARMACEUTICAL AND LIFE SCIENCES COMPANIES OPTIMIZE COMMERCIALIZATION OF BIOMARKER-TARGETED THERAPIES IN ONCOLOGY Source text for Eikon: Further company coverage:

18 Dec 2018

Earnings vs. Estimates